Skip to main content
Clinical Trials/NCT01232842
NCT01232842
Completed
Not Applicable

Assessment of Stem Cell Heterogeneity in AML in Co-Culture Systems Using X Chromosome Inactivation Patterns

Children's Oncology Group0 sites20 target enrollmentOctober 2010
ConditionsLeukemia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Leukemia
Sponsor
Children's Oncology Group
Enrollment
20
Primary Endpoint
Frequency of AML that originate in CD33+ or in which uncontrolled growth is restricted to CD33+ precursors
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in tissue samples from patients with acute myeloid leukemia.

Detailed Description

OBJECTIVES: * Determine the frequency of acute myeloid leukemia (AML) that originates in CD33+ precursors or in which uncontrolled growth is restricted to CD33+ precursors. OUTLINE: Cryopreserved acute myeloid leukemia cell samples are separated from endothelial cell by fluorescent-activated cell sorting (FACS) and analyzed for X-chromosome inactivation patterns by cytogenetic/molecular analysis and/or Humara assay.

Registry
clinicaltrials.gov
Start Date
October 2010
End Date
July 2016
Last Updated
9 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Frequency of AML that originate in CD33+ or in which uncontrolled growth is restricted to CD33+ precursors

Extent of clonal hematopoiesis in small numbers of AML cells

Similar Trials